Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta, Tel Aviv University to Collaborate on microRNA Drug Delivery Tech


Rosetta Genomics said this week that it has entered a sponsored research arrangement with Tel Aviv University tech-transfer subsidiary Ramot to develop a delivery technology for microRNA mimic-based cancer therapies.

The deal calls for the partners to work together for one year and jointly own data and intellectual property resulting from the alliance. Rosetta will contribute around $69,000 to fund research at Ramot.

Although Rosetta was founded to develop both miRNA diagnostics and therapeutics, the company has largely focused on its diagnostics efforts. However, it has been working with Ramot for several years on miRNA mimics, including one based on miR-34a for cancer (GSN 8/8/2013).